Patents Assigned to Biovitrum AB
-
Patent number: 8986759Abstract: The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds.Type: GrantFiled: October 21, 2011Date of Patent: March 24, 2015Assignee: Swedish Orphan Biovitrum AB (pub)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, M{hacek over (a)}rten Vågerö, Maria Öhman
-
Publication number: 20140186921Abstract: The invention relates to a process for recovering and purifying bile salt-stimulated lipase (BSSL) in a solution which contains impurities, said process comprising the steps: (i) applying BSSL to a hydrophobic interaction chromatography (HIC) resin; (ii) removing impurities by washing said HIC resin with a wash composition having a pH in the range from 4 to 5; and (iii) recovering BSSL from said HIC resin.Type: ApplicationFiled: May 15, 2012Publication date: July 3, 2014Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)Inventors: Thomas Strömquist, Susanne Wood
-
Patent number: 8686011Abstract: The present invention relates to compounds with the formula (I), (II), (III) or (IV): wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.Type: GrantFiled: September 15, 2011Date of Patent: April 1, 2014Assignees: Amgen Inc., Biovitrum ABInventors: Martin Henriksson, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric A. Bercot, Christopher H. Fotsch, Aiwen Li, Guolin Cai, Randall W. Hungate, Chester Chenguang Yuan, Christopher Tegley, David J. St. Jean, Jr., Nianhe Han, Qi Huang, Qingyian Liu, Michael D. Bartberger, George A. Moniz, Matthew J. Frizzle
-
Publication number: 20140018298Abstract: The present invention relates to pharmaceutical compositions comprising anakinra as an active compound in the absence of sodium citrate. The said pharmaceutical compositions are useful for the treatment of IL-1 mediated disorders and for decreasing nociceptive pain during such treatment.Type: ApplicationFiled: February 9, 2012Publication date: January 16, 2014Applicant: Swedish Orphan Biovitrum AB (Publ)Inventors: Jonas Fransson, Ebba Florin-Robertsson
-
Patent number: 8544682Abstract: A device for the serial ejection of at least two fluid components comprises a spacer (19) providing at least two states, i) a first state allowing a front piston (7) to be displaced forwards by action on a rear piston (17) while a fluid volume is retained in a rear chamber (5) and ii) a second state allowing the rear chamber to volumetrically shrink while fluid is transferred past (or through) the front piston thereby enabling the use of a liquid, initially provided in only the rear chamber, for the dual purposes of mixing and rinsing.Type: GrantFiled: November 21, 2008Date of Patent: October 1, 2013Assignee: Swedish Orphan Biovitrum ABInventors: Jonas Fransson, Birger Hjertman
-
Patent number: 8541592Abstract: The present invention relates to thiazolinones and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-?-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.Type: GrantFiled: November 13, 2006Date of Patent: September 24, 2013Assignees: Amgen Inc., Biovitrum ABInventors: Martin Henriksson, Evert Homan, Lars Johansson, Jerk Vallgarda, Meredith Williams, Eric A. Bercot, Christopher H. Fotsch, Aiwen Li, Guolin Cai, Randall W. Hungate, Chester Chenguang Yuan, Christopher Tegley, David J. St. Jean, Jr., Nianhe Han, Qi Huang, Qingyian Liu, Michael D. Bartberger, George A. Moniz, Matthew J. Frizzle, Teresa L. Marshall
-
Publication number: 20130158266Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.Type: ApplicationFiled: February 15, 2013Publication date: June 20, 2013Applicant: BIOVITRUM AB (PUBL)Inventor: Biovitrum AB (publ)
-
Patent number: 8410113Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.Type: GrantFiled: September 16, 2011Date of Patent: April 2, 2013Assignee: Biovitrum AB (publ)Inventors: Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren, Bruce Fleck
-
Patent number: 8304387Abstract: The present invention provides long-term stable formulations of lyophilized keratinocyte growth factor and methods for making a lyophilized composition comprising keratinocyte growth factor.Type: GrantFiled: December 12, 2005Date of Patent: November 6, 2012Assignee: Swedish Orphan Biovitrum AB (publ)Inventors: Michael J. Treuheit, Vasumathi Dharmavaram, Judith Purtell, Suzanne E. Roy
-
Publication number: 20120100126Abstract: The present invention relates to a method to increase the growth velocity of a human infant, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). Such method has particular utility for underweight or preterm human infants, particular those in medical need of increasing their growth velocity. The invention also relates to compositions, including infant feeds, kits, packaged-pharmaceutical-products and pharmaceutical compositions, and also to methods to prepare infant feeds.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: SWEDISH ORPHAN BIOVITRUM AB (publ)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, Mårten Vågerö, Maria Öhman
-
Publication number: 20120100127Abstract: The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant.Type: ApplicationFiled: October 21, 2011Publication date: April 26, 2012Applicant: SWEDISH ORPHAN BIOVITRUM AB (publ)Inventors: Olle Hernell, Birgitta Olsson, Patrik Strömberg, Lennart Svensson, Kristina Timdahl, Mårten Vågerö, Maria Öhman
-
Patent number: 8030316Abstract: The present invention relates to a process for the preparation of compounds which are therapeutically active in the central nervous system. In one aspect, the invention relates to a process for the preparation of compounds of the general formula (I): wherein HA is a pharmaceutically acceptable acid and R1-R4 are each independently selected from the group consisting of hydrogen, halogen, C1-C6-alkyl, C1-C6-alkoxy, and di-C1-C6-alkylamino-C2-C6-alkoxy. The invention also relates to the use of said compound to manufacture a medicament for the treatment of a serotonin-related disorder.Type: GrantFiled: June 17, 2010Date of Patent: October 4, 2011Assignee: Biovitrum AB (Publ)Inventors: Tom Fleck, Bruce Fleck, legal representative, Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren
-
Publication number: 20110015185Abstract: The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.Type: ApplicationFiled: September 28, 2010Publication date: January 20, 2011Applicant: BIOVITRUM ABInventors: Gary Johansson, Peter Brandt, Björn M. Nilsson
-
Patent number: 7820675Abstract: The present invention relates to compounds of formula (I): wherein P, R3, W1, and W2 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.Type: GrantFiled: December 20, 2004Date of Patent: October 26, 2010Assignee: Biovitrum ABInventors: Gary Johansson, Peter Brandt, Björn M. Nilsson
-
Patent number: 7812017Abstract: The present invention relates to novel compounds of formula (I): wherein m, n, R0, R1, R2, R3 and R4 are as described herein, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HT6 receptor-related disorders.Type: GrantFiled: July 3, 2007Date of Patent: October 12, 2010Assignee: Biovitrum AB (publ.)Inventors: Johan Angbrant, Rune Ringom, Kristin Hammer, Erik Ringberg, Bengt Lindqvist, Gary Johansson, Peter Brandt, Katarina Beierlein, Björn M Nilsson
-
Publication number: 20100222330Abstract: The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.Type: ApplicationFiled: May 17, 2010Publication date: September 2, 2010Applicant: BIOVITRUM ABInventors: Patrizia Caldirola, Gary Johansson, Andrew Mott, Katarina Beierlein, Markus Thor, Lars Tedenborg, Ulf Bremberg, Annika Jenmalm Jensen
-
Patent number: 7718650Abstract: The present invention relates to substituted bis-arylsulfonamide and arylsulfonamide compounds of the general formula (I) or the formula (II), which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.Type: GrantFiled: December 19, 2007Date of Patent: May 18, 2010Assignee: Biovitrum ABInventors: Ulf Bremberg, Patrizia Caldirola, Annika J. Jensen, Gary Johansson, Lori Sutin, Andrew Mott, Jan Tejbrant
-
Patent number: 7709526Abstract: Compounds which inhibit the insulin-like growth factor-1 receptor (IGF-1 R) and methods for using them for treating IGF-1 R dependent diseases, such as cancer.Type: GrantFiled: February 3, 2006Date of Patent: May 4, 2010Assignee: Biovitrum ABInventors: Olle Larsson, Magnus Axelson
-
Patent number: 7671051Abstract: The present invention relates to compounds with the formula (I) and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme.Type: GrantFiled: July 13, 2005Date of Patent: March 2, 2010Assignee: Biovitrum ABInventors: Tjeerd Barf, Rikard Emond, Jerk Vallgarda, Guido Kurz, Marianne Nilsson, Lian Zhang
-
Patent number: 7666888Abstract: Compounds of formula I and IV are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorder: wherein the variables A-B, R1, R2, m, and Q are described herein.Type: GrantFiled: July 18, 2007Date of Patent: February 23, 2010Assignees: Amgen Inc., Biovitrum ABInventors: Michael D. Bartberger, Christopher H. Fotsch, Martin Haraldsson, David St. Jean, Lars Johansson, Marianne Nilsson, Lori Sutin, Katrina Flyrén